Halston Deal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Halston Deal has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Michael A. Daniele
North Carolina Viral Vector Initiative in Research and Learning (NC‐VVIRAL) NC State University Raleigh North Carolina USA
2 shared publications - Adriana San-Miguel
North Carolina State University
1 shared publication - Ashley C. Brown
Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Raleigh, USA
1 shared publication Ashley Carson Brown
Joint Department of Biomedical Engineering North Carolina State University and University of North Carolina at Chapel Hill 911 Oval Drive Raleigh NC 27695 USA
1 shared publication- Brandyn David Moore
Department of Chemical and Biomolecular Engineering, North Carolina State University
1 shared publication Elizabeth M. Byrnes
Joint Department of Biomedical Engineering North Carolina State University and University of North Carolina Raleigh North Carolina USA
1 shared publication
Latest Publications
- Open Access
- 15 February 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (37)
Microfluidic Platform for Multiparametric Profiling of Fibrin Permeability, Fibrinolysis, and Cell Invasion
Fibrin's dual role, as a transient scaffold guiding wound repair and as a pathogenic matrix in thrombosis, demands tools that can profile how its transport properties, degradability, and cellular remodeling evolve under different biochemical, engineering, and ultimately patient‐specific conditions. Here, we introduce a single‐channel, H‐junction microfluidic platform that enables multiplexed, real‐time quantification of fibrin permeability, fibrinolysis kinetics, fibroblast invasion, and clot extension within the same hydrogel. Using time‐lapse confocal microscopy, the assay captured solute permeability coefficients from 1.98 × 10 −5 to 1.67 × 10 −4 cm 2 ∙s −1 , fibrinolysis half‐times down to 12 min, and cell migration, with quantitative analysis performed in a ∼3 µL gel volume. Systematic variation of fibrinogen concentration (1.5–10 mg∙mL −1 ) and FXIII crosslink density reveals a 3.7‐fold span in permeability, a ninefold shift in lysis rate, and up to 64% suppression of fibroblast penetration, as fibrinogen concentration increases. Because the chip uses standard soft‐lithography and conventional microscopy tools, it can be integrated into existing microphysiological systems or deployed as a high‐throughput screening tool for anticoagulants, pro‐healing therapies, and patient‐specific risk assessment. This versatile platform thus bridges mechanistic fibrin research and translational biomaterials design, opening new avenues for precision thrombosis modelling and regenerative medicine.
- 15 February 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (37)
Open AccessMicrofluidic Platform for Multiparametric Profiling of Fibrin Permeability, Fibrinolysis, and Cell Invasion
Fibrin's dual role, as a transient scaffold guiding wound repair and as a pathogenic matrix in thrombosis, demands tools that can profile how its transport properties, degradability, and cellular remodeling evolve under different biochemical, engineering, and ultimately patient‐specific conditions. Here, we introduce a single‐channel, H‐junction microfluidic platform that enables multiplexed, real‐time quantification of fibrin permeability, fibrinolysis kinetics, fibroblast invasion, and clot extension within the same hydrogel. Using time‐lapse confocal microscopy, the assay captured solute permeability coefficients from 1.98 × 10 −5 to 1.67 × 10 −4 cm 2 ∙s −1 , fibrinolysis half‐times down to 12 min, and cell migration, with quantitative analysis performed in a ∼3 µL gel volume. Systematic variation of fibrinogen concentration (1.5–10 mg∙mL −1 ) and FXIII crosslink density reveals a 3.7‐fold span in permeability, a ninefold shift in lysis rate, and up to 64% suppression of fibroblast penetration, as fibrinogen concentration increases. Because the chip uses standard soft‐lithography and conventional microscopy tools, it can be integrated into existing microphysiological systems or deployed as a high‐throughput screening tool for anticoagulants, pro‐healing therapies, and patient‐specific risk assessment. This versatile platform thus bridges mechanistic fibrin research and translational biomaterials design, opening new avenues for precision thrombosis modelling and regenerative medicine.
- Open Access
- 25 January 2023
- Published by Wiley in Advanced Functional Materials
- Vol. 33 (14)
Molecular Engineering of Cyclic Azobenzene‐Peptide Hybrid Ligands for the Purification of Human Blood Factor VIII via Photo‐Affinity Chromatography
The use of benign stimuli to control the binding and release of labile biologics for their isolation from complex feedstocks is a key goal of modern biopharmaceutical technology. This study introduces cyclic azobenzene‐peptide (CAP) ligands for the rapid and discrete photo‐responsive capture and release of blood coagulation factor VIII (FVIII). A predictive method—based on amino acid sequence and molecular architecture of CAPs—is developed to correlate the conformation of cis/trans‐CAP photo‐isomers to FVIII binding and release. Combined in silico ‐ in vitro analysis of FVIII:peptide interactions guide the design of a rational approach to optimize isomerization kinetics and biorecognition of CAPs. A photoaffinity adsorbent, prepared by conjugating selected CAP G‐cycloAZOB[Lys‐YYKHLYN‐Lys]‐G on translucent chromatographic beads, features high binding capacity (>6 mg of FVIII per mL of resin) and rapid photo‐isomerization kinetics (τ < 30 s) when exposed to 420–450 nm light at the intensity of 0.1 W cm−2. The adsorbent purifies FVIII from a recombinant harvest using a single mobile phase, affording high product yield (>90%), purity (>95%), and blood clotting activity. The CAPs introduced in this report demonstrate a novel route integrating gentle operational conditions in a rapid and efficient bioprocess for the purification of life‐saving biotherapeutics.
- 25 January 2023
- Published by Wiley in Advanced Functional Materials
- Vol. 33 (14)
Open AccessMolecular Engineering of Cyclic Azobenzene‐Peptide Hybrid Ligands for the Purification of Human Blood Factor VIII via Photo‐Affinity Chromatography
The use of benign stimuli to control the binding and release of labile biologics for their isolation from complex feedstocks is a key goal of modern biopharmaceutical technology. This study introduces cyclic azobenzene‐peptide (CAP) ligands for the rapid and discrete photo‐responsive capture and release of blood coagulation factor VIII (FVIII). A predictive method—based on amino acid sequence and molecular architecture of CAPs—is developed to correlate the conformation of cis/trans‐CAP photo‐isomers to FVIII binding and release. Combined in silico ‐ in vitro analysis of FVIII:peptide interactions guide the design of a rational approach to optimize isomerization kinetics and biorecognition of CAPs. A photoaffinity adsorbent, prepared by conjugating selected CAP G‐cycloAZOB[Lys‐YYKHLYN‐Lys]‐G on translucent chromatographic beads, features high binding capacity (>6 mg of FVIII per mL of resin) and rapid photo‐isomerization kinetics (τ < 30 s) when exposed to 420–450 nm light at the intensity of 0.1 W cm−2. The adsorbent purifies FVIII from a recombinant harvest using a single mobile phase, affording high product yield (>90%), purity (>95%), and blood clotting activity. The CAPs introduced in this report demonstrate a novel route integrating gentle operational conditions in a rapid and efficient bioprocess for the purification of life‐saving biotherapeutics.